US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Kyverna Therapeutics

8.42

+0.29003.57%

Post-market: 8.450.0320+0.38%19:30 EDT

Volume:663.61K

Turnover:5.56M

Market Cap:520.72M

PE:-2.92

High:8.58

Open:8.24

Low:8.19

Close:8.13

52wk High:13.67

52wk Low:3.50

Shares:61.84M

Float Shares:39.72M

Volume Ratio:0.77

T/O Rate:1.67%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.8809

EPS(LYR):-3.6445

ROE:-87.24%

ROA:-44.51%

PB:3.15

PE(LYR):-2.31

Loading ...

Overview Company News Filings

BUZZ-U.S. STOCKS ON THE MOVE-Adobe, GE Vernova, Calix

Top Premarket Gainers

MT Newswires Live

Kyverna Shares Rise Premarket After Promising Trial of Neurological Product

BUZZ-Kyverna jumps as rare muscle disorder cell therapy shows strong mid-stage results

Kyverna Therapeutics Shares Jump 21% Premarket After Co's Therapy Improves Mobility in Mid-Stage Stiff Person Syndrome Trial

THOMSON REUTERS

Kyverna Therapeutics (KYTX) Stock Surges 24% After Hours: Why Is It Moving?

Benzinga Earnings

BRIEF-Kyverna Therapeutics Announces Positive Primary Analysis Results From KYSA-8 Trial Of Miv-Cel In SPS

Kyverna Therapeutics Inc - Trial Meets All Secondary Endpoints With Significant Improvements in SPS

THOMSON REUTERS

Kyverna Therapeutics Inc - Announces Positive Primary Analysis Results From Kysa-8 Trial of Miv-Cel in SPS

THOMSON REUTERS

Kyverna says miv-cel meets primary endpoint in stiff person syndrome trial

Kyverna Shares Rise on Positive Long-Term Trial Results

Kyverna Therapeutics presents longer-term Phase 2 data for Miv-cel

Kyverna says miv-cel shows durable gMG responses through 52 weeks in Phase 2 KYSA-6 trial

Kyverna Therapeutics Inc - 100% of Patients Achieved Rapid, Sustained Improvements in Mg-Adl and Qmg at 24 Weeks

THOMSON REUTERS

Kyverna Therapeutics Inc - Announces Positive Longer-Term Phase 2 Data for Miv-Cel in Generalized Myasthenia Gravis

THOMSON REUTERS

Kyverna Therapeutics announces annual shareholder meeting via webcast

Kyverna to present pivotal KYSA-8 miv-cel data in stiff person syndrome at AAN

Kyverna Therapeutics to Host Conference Call on New Data Across Neuroimmunology Franchise at AAN 2026

BRIEF-Kyverna Therapeutics Enters Open Market Sale Agreement With Jefferies Dated March 27, 2025 - SEC Filing

J.P. Morgan Sticks to Their Buy Rating for Kyverna Therapeutics, Inc. (KYTX)

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/KYTX/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"KYTX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KYTX\",,,,,undefined,":{"symbol":"KYTX","market":"US","secType":"STK","nameCN":"Kyverna Therapeutics","latestPrice":8.42,"timestamp":1787342400000,"preClose":8.13,"halted":0,"volume":663612,"hourTrading":{"tag":"盘后","latestPrice":8.452,"preClose":8.42,"latestTime":"19:30 EDT","volume":9637,"amount":81149.3365,"timestamp":1787355006604,"change":0.032,"changeRate":0.0038,"amplitude":0.0038},"delay":0,"changeRate":0.03567035670356693,"floatShares":39715000,"shares":61843444,"eps":-2.880877,"marketStatus":"Market Closed","change":0.29,"latestTime":"08-21 16:00:00 EDT","open":8.24,"high":8.58,"low":8.19,"amount":5556268.322597999,"amplitude":0.04797,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.880877,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1787558400000},"marketStatusCode":7,"adr":0,"listingDate":1707368400000,"exchange":"NASDAQ","adjPreClose":8.13,"preHourTrading":{"tag":"盘前","latestPrice":8.24,"preClose":8.13,"latestTime":"09:22 EDT","volume":457,"amount":3796.3766899999996,"timestamp":1787318544349,"change":0.11,"changeRate":0.01353,"amplitude":0.121771},"postHourTrading":{"tag":"盘后","latestPrice":8.452,"preClose":8.42,"latestTime":"19:30 EDT","volume":9637,"amount":81149.3365,"timestamp":1787355006604,"change":0.032,"changeRate":0.0038,"amplitude":0.0038},"volumeRatio":0.7667172178993392,"impliedVol":1.1525,"impliedVolPercentile":0.4183},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KYTX\",,,,,undefined,":{"symbol":"KYTX","floatShares":39715000,"roa":"-44.51%","roe":"-87.24%","lyrEps":-3.644532,"volumeRatio":0.7667172178993392,"shares":61843444,"dividePrice":0,"high":8.58,"amplitude":0.04797,"preClose":8.13,"low":8.19,"week52Low":3.5,"pbRate":"3.15","psRate":"1846.53","week52High":13.67,"institutionHeld":0,"latestPrice":8.42,"eps":-2.880877,"divideRate":0,"volume":663612,"delay":0,"ttmEps":-2.880877,"open":8.24,"prevYearClose":9.4,"prevWeekClose":8.17,"prevMonthClose":7.3,"prevQuarterClose":8.91,"fiveDayClose":8.17,"twentyDayClose":7.41,"sixtyDayClose":8.59},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/KYTX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-11","symbol":"KYTX","fiscalQuarterEnding":"2026/06","expectedEps":-0.67,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1786420800000,"reportTimeType":"post","actualEps":-0.63},{"market":"US","date":"2026-05-12","symbol":"KYTX","fiscalQuarterEnding":"2026/03","expectedEps":-0.75,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778558400000,"reportTimeType":"post","actualEps":-0.66},{"market":"US","date":"2026-03-26","symbol":"KYTX","fiscalQuarterEnding":"2025/12","expectedEps":-0.8,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1774497600000,"reportTimeType":"post","actualEps":-0.8},{"market":"US","date":"2025-11-12","symbol":"KYTX","fiscalQuarterEnding":"2025/09","expectedEps":-0.97,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1762923600000,"reportTimeType":"post","actualEps":-0.85},{"market":"US","date":"2025-08-12","symbol":"KYTX","fiscalQuarterEnding":"2025/06","expectedEps":1,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1754971200000,"reportTimeType":"post","actualEps":-0.97}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"KYTX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"KYTX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3333,"buy":0.6667,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6667,"analysts":6,"updateTime":1755748800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/KYTX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"KYTX","date":"2026-08-21","current":-2.922721,"percent":0.334385,"low":-26.836094,"twenty":-4.227182,"median":-2.842423,"eighty":-1.108015,"high":-0.615209,"avg":-4.328161,"sd":5.693054,"marketCap":502787199},"quantilePoints":[{"date":"2024-02-09","current":-25.410847,"twenty":-24.055602,"median":-22.022734,"eighty":-19.989866,"marketCap":1224675750},{"date":"2024-02-16","current":-26.541682,"twenty":-26.641604,"median":-26.505996,"eighty":-25.427787,"marketCap":1279176368},{"date":"2024-02-23","current":-24.230994,"twenty":-26.541682,"median":-25.495549,"eighty":-24.578936,"marketCap":1167812779},{"date":"2024-03-01","current":-24.239916,"twenty":-26.505996,"median":-25.105309,"eighty":-24.54325,"marketCap":1168242754},{"date":"2024-03-08","current":-25.676289,"twenty":-26.318643,"median":-25.069622,"eighty":-24.578936,"marketCap":1237468769},{"date":"2024-03-15","current":-26.354329,"twenty":-26.354329,"median":-25.311608,"eighty":-24.712759,"marketCap":1270146888},{"date":"2024-03-22","current":-23.999034,"twenty":-26.354329,"median":-25.16776,"eighty":-24.239916,"marketCap":1156633422},{"date":"2024-03-28","current":-17.2201,"twenty":-26.32578,"median":-25.042858,"eighty":-23.820602,"marketCap":1039508532},{"date":"2024-04-05","current":-15.927342,"twenty":-26.311505,"median":-24.815357,"eighty":-20.313915,"marketCap":961469941},{"date":"2024-04-12","current":-17.062969,"twenty":-25.959995,"median":-24.578936,"eighty":-17.608641,"marketCap":1030023179},{"date":"2024-04-19","current":-13.577524,"twenty":-25.715544,"median":-24.235455,"eighty":-16.573007,"marketCap":819620788},{"date":"2024-04-26","current":-11.384836,"twenty":-25.597779,"median":-23.86521,"eighty":-16.071617,"marketCap":687256989},{"date":"2024-05-03","current":-10.734886,"twenty":-25.51207,"median":-23.093494,"eighty":-15.443094,"marketCap":648022117},{"date":"2024-05-10","current":-10.427767,"twenty":-25.427787,"median":-18.634621,"eighty":-13.461819,"marketCap":629482562},{"date":"2024-05-17","current":-8.660987,"twenty":-25.252064,"median":-17.663681,"eighty":-11.317698,"marketCap":657507471},{"date":"2024-05-24","current":-7.059414,"twenty":-25.176682,"median":-17.2201,"eighty":-10.732029,"marketCap":535922482},{"date":"2024-05-31","current":-7.116207,"twenty":-25.108877,"median":-16.627288,"eighty":-10.256351,"marketCap":540234007},{"date":"2024-06-07","current":-7.456968,"twenty":-25.053564,"median":-16.309455,"eighty":-9.030538,"marketCap":566103153},{"date":"2024-06-14","current":-5.412407,"twenty":-25.026799,"median":-16.020192,"eighty":-8.479248,"marketCap":410888275},{"date":"2024-06-21","current":-4.390126,"twenty":-24.958995,"median":-15.870204,"eighty":-7.953341,"marketCap":333280836},{"date":"2024-06-28","current":-4.259502,"twenty":-24.826956,"median":-14.259614,"eighty":-7.613717,"marketCap":323364330},{"date":"2024-07-05","current":-3.978375,"twenty":-24.748445,"median":-13.641804,"eighty":-7.429707,"marketCap":302022284},{"date":"2024-07-12","current":-5.56007,"twenty":-24.685994,"median":-12.649024,"eighty":-7.150283,"marketCap":422098238},{"date":"2024-07-19","current":-5.685015,"twenty":-24.571799,"median":-11.216991,"eighty":-6.028046,"marketCap":431583592},{"date":"2024-07-26","current":-5.588466,"twenty":-24.482583,"median":-10.813451,"eighty":-5.596417,"marketCap":424254000},{"date":"2024-08-02","current":-4.117518,"twenty":-24.238132,"median":-10.584898,"eighty":-5.421494,"marketCap":312585519},{"date":"2024-08-09","current":-3.725644,"twenty":-24.184602,"median":-9.999228,"eighty":-5.056881,"marketCap":282836000},{"date":"2024-08-16","current":-3.830678,"twenty":-23.972269,"median":-9.395703,"eighty":-4.700218,"marketCap":290809782},{"date":"2024-08-23","current":-4.597951,"twenty":-23.820602,"median":-8.80297,"eighty":-4.562778,"marketCap":349058032},{"date":"2024-08-30","current":-4.56385,"twenty":-23.561877,"median":-8.433813,"eighty":-4.558634,"marketCap":346469221},{"date":"2024-09-06","current":-4.171688,"twenty":-23.2407,"median":-8.189602,"eighty":-4.480996,"marketCap":316697893},{"date":"2024-09-13","current":-4.092119,"twenty":-22.946288,"median":-7.78069,"eighty":-4.395806,"marketCap":310657334},{"date":"2024-09-20","current":-3.631756,"twenty":-20.733738,"median":-7.624508,"eighty":-4.308092,"marketCap":275708384},{"date":"2024-09-27","current":-2.97247,"twenty":-18.634621,"median":-7.456968,"eighty":-4.211473,"marketCap":225658035},{"date":"2024-10-04","current":-2.63146,"twenty":-17.741488,"median":-7.394495,"eighty":-4.171688,"marketCap":199769924},{"date":"2024-10-11","current":-2.983837,"twenty":-17.707293,"median":-7.116207,"eighty":-4.052335,"marketCap":226520973},{"date":"2024-10-18","current":-3.205494,"twenty":-17.620069,"median":-6.641982,"eighty":-3.978375,"marketCap":243348245},{"date":"2024-10-25","current":-2.909952,"twenty":-17.56293,"median":-5.951944,"eighty":-3.964176,"marketCap":220911882},{"date":"2024-11-01","current":-2.779231,"twenty":-17.2201,"median":-5.608344,"eighty":-3.873307,"marketCap":210988106},{"date":"2024-11-08","current":-3.006571,"twenty":-17.062969,"median":-5.514635,"eighty":-3.751109,"marketCap":228246847},{"date":"2024-11-15","current":-1.697135,"twenty":-16.627288,"median":-5.392529,"eighty":-3.322005,"marketCap":187796512},{"date":"2024-11-22","current":-1.712741,"twenty":-16.355881,"median":-5.065967,"eighty":-3.177076,"marketCap":189523376},{"date":"2024-11-29","current":-2.251143,"twenty":-16.350167,"median":-4.969419,"eighty":-3.054313,"marketCap":249100201},{"date":"2024-12-06","current":-1.775165,"twenty":-16.285886,"median":-4.789428,"eighty":-3.003161,"marketCap":196430834},{"date":"2024-12-13","current":-1.724446,"twenty":-16.121613,"median":-4.674093,"eighty":-2.977017,"marketCap":190818525},{"date":"2024-12-20","current":-1.560584,"twenty":-16.033048,"median":-4.573541,"eighty":-2.950873,"marketCap":172686448},{"date":"2024-12-27","current":-1.556683,"twenty":-15.964482,"median":-4.562178,"eighty":-2.903132,"marketCap":172254731},{"date":"2025-01-03","current":-1.599599,"twenty":-15.904487,"median":-4.538274,"eighty":-2.797418,"marketCap":177003609},{"date":"2025-01-10","current":-1.346004,"twenty":-15.82735,"median":-4.480996,"eighty":-2.693979,"marketCap":148942061},{"date":"2025-01-17","current":-1.299186,"twenty":-15.443094,"median":-4.435561,"eighty":-2.615547,"marketCap":143761467},{"date":"2025-01-24","current":-1.404526,"twenty":-14.591731,"median":-4.395806,"eighty":-2.532048,"marketCap":155417803},{"date":"2025-01-31","current":-1.264073,"twenty":-13.927497,"median":-4.353211,"eighty":-2.095084,"marketCap":139876022},{"date":"2025-02-07","current":-1.170438,"twenty":-13.706085,"median":-4.259502,"eighty":-1.931223,"marketCap":129514836},{"date":"2025-02-14","current":-1.182143,"twenty":-13.577524,"median":-4.21845,"eighty":-1.814179,"marketCap":130809984},{"date":"2025-02-21","current":-1.084606,"twenty":-13.114702,"median":-4.187318,"eighty":-1.73693,"marketCap":120017081},{"date":"2025-02-28","current":-1.108015,"twenty":-12.719019,"median":-4.171688,"eighty":-1.688552,"marketCap":122607378},{"date":"2025-03-07","current":-1.01438,"twenty":-12.020501,"median":-4.104819,"eighty":-1.598038,"marketCap":112246191},{"date":"2025-03-14","current":-0.975365,"twenty":-11.480543,"median":-3.998252,"eighty":-1.555903,"marketCap":107929030},{"date":"2025-03-21","current":-0.928548,"twenty":-11.116285,"median":-3.978412,"eighty":-1.525471,"marketCap":102748436},{"date":"2025-03-28","current":-0.678003,"twenty":-10.923443,"median":-3.972766,"eighty":-1.481775,"marketCap":86429836},{"date":"2025-04-04","current":-0.671223,"twenty":-10.829164,"median":-3.959945,"eighty":-1.403746,"marketCap":85565537},{"date":"2025-04-11","current":-0.698343,"twenty":-10.750599,"median":-3.915931,"eighty":-1.33508,"marketCap":89022731},{"date":"2025-04-17","current":-0.630601,"twenty":-10.726315,"median":-3.836362,"eighty":-1.299186,"marketCap":80387103},{"date":"2025-04-25","current":-0.711969,"twenty":-10.557757,"median":-3.76816,"eighty":-1.283581,"marketCap":90759633},{"date":"2025-05-02","current":-0.772995,"twenty":-10.436338,"median":-3.711325,"eighty":-1.243785,"marketCap":98539030},{"date":"2025-05-09","current":-0.715359,"twenty":-10.170644,"median":-3.266591,"eighty":-1.184484,"marketCap":91191822},{"date":"2025-05-16","current":-0.68951,"twenty":-9.982087,"median":-3.188443,"eighty":-1.152492,"marketCap":100267785},{"date":"2025-05-23","current":-0.73409,"twenty":-9.837812,"median":-3.142975,"eighty":-1.119719,"marketCap":106750616},{"date":"2025-05-30","current":-0.781642,"twenty":-9.466412,"median":-3.049198,"eighty":-1.09553,"marketCap":113665635},{"date":"2025-06-06","current":-0.873775,"twenty":-9.030538,"median":-3.023622,"eighty":-1.030766,"marketCap":127063486},{"date":"2025-06-13","current":-1.02832,"twenty":-8.929052,"median":-2.986679,"eighty":-1.018767,"marketCap":149537300},{"date":"2025-06-20","current":-0.864859,"twenty":-8.793883,"median":-2.980995,"eighty":-1.008108,"marketCap":125766920},{"date":"2025-06-27","current":-1.031292,"twenty":-8.738225,"median":-2.966787,"eighty":-0.98785,"marketCap":149969489},{"date":"2025-07-03","current":-0.835139,"twenty":-8.660987,"median":-2.95542,"eighty":-0.975365,"marketCap":121445033},{"date":"2025-07-11","current":-1.061012,"twenty":-8.20664,"median":-2.912794,"eighty":-0.974824,"marketCap":154291376},{"date":"2025-07-18","current":-1.209614,"twenty":-8.200961,"median":-2.836066,"eighty":-0.975365,"marketCap":175900813},{"date":"2025-07-25","current":-1.260138,"twenty":-8.178243,"median":-2.779231,"eighty":-0.975365,"marketCap":183248021},{"date":"2025-08-01","current":-1.061012,"twenty":-7.803407,"median":-2.688295,"eighty":-0.975365,"marketCap":154291376},{"date":"2025-08-08","current":-0.98374,"twenty":-7.78069,"median":-2.625776,"eighty":-0.98374,"marketCap":143054469},{"date":"2025-08-15","current":-0.964666,"twenty":-7.68982,"median":-2.585992,"eighty":-0.974824,"marketCap":153089661},{"date":"2025-08-22","current":-0.975567,"twenty":-7.678462,"median":-2.530603,"eighty":-0.962936,"marketCap":154819487},{"date":"2025-08-29","current":-1.008267,"twenty":-7.570554,"median":-2.118493,"eighty":-0.964666,"marketCap":160008967},{"date":"2025-09-05","current":-0.989192,"twenty":-7.52512,"median":-1.993646,"eighty":-0.964666,"marketCap":156981771},{"date":"2025-09-12","current":-1.130894,"twenty":-7.468327,"median":-1.952681,"eighty":-0.972792,"marketCap":179469518},{"date":"2025-09-19","current":-1.365248,"twenty":-7.429707,"median":-1.872701,"eighty":-0.975257,"marketCap":216660791},{"date":"2025-09-26","current":-1.730404,"twenty":-7.422892,"median":-1.802474,"eighty":-0.975365,"marketCap":274609985},{"date":"2025-10-03","current":-1.656828,"twenty":-7.377457,"median":-1.775165,"eighty":-0.975365,"marketCap":262933655},{"date":"2025-10-10","current":-1.923883,"twenty":-7.30249,"median":-1.765048,"eighty":-0.975527,"marketCap":305314409},{"date":"2025-10-17","current":-1.910257,"twenty":-7.150283,"median":-1.79077,"eighty":-0.977747,"marketCap":303152125},{"date":"2025-10-24","current":-1.74403,"twenty":-7.070773,"median":-1.806706,"eighty":-0.98265,"marketCap":276772268},{"date":"2025-10-31","current":-1.839406,"twenty":-7.009436,"median":-1.817606,"eighty":-0.98374,"marketCap":291908252},{"date":"2025-11-07","current":-1.932058,"twenty":-6.429007,"median":-1.834596,"eighty":-0.986404,"marketCap":306611779},{"date":"2025-11-14","current":-1.76583,"twenty":-6.028046,"median":-1.829785,"eighty":-0.98707,"marketCap":280231922},{"date":"2025-11-21","current":-2.023973,"twenty":-5.954216,"median":-1.856881,"eighty":-0.988768,"marketCap":325843504},{"date":"2025-11-28","current":-2.086542,"twenty":-5.791787,"median":-1.873766,"eighty":-0.989487,"marketCap":335916623},{"date":"2025-12-05","current":-2.132789,"twenty":-5.650939,"median":-1.874832,"eighty":-0.990456,"marketCap":343361972},{"date":"2025-12-12","current":-2.27425,"twenty":-5.604368,"median":-1.895008,"eighty":-0.995653,"marketCap":366135981},{"date":"2025-12-19","current":-1.904276,"twenty":-5.571428,"median":-1.899357,"eighty":-1.000453,"marketCap":306573190},{"date":"2025-12-26","current":-2.445634,"twenty":-5.541896,"median":-1.907532,"eighty":-1.00316,"marketCap":393727568},{"date":"2026-01-02","current":-3.335677,"twenty":-5.503276,"median":-1.923883,"eighty":-1.005937,"marketCap":537017328},{"date":"2026-01-09","current":-2.998561,"twenty":-5.448754,"median":-1.93164,"eighty":-1.007666,"marketCap":482744300},{"date":"2026-01-16","current":-3.094373,"twenty":-5.404456,"median":-1.947802,"eighty":-1.008709,"marketCap":498169266},{"date":"2026-01-23","current":-3.729571,"twenty":-5.372651,"median":-1.953858,"eighty":-1.010478,"marketCap":600431076},{"date":"2026-01-30","current":-2.913395,"twenty":-5.344255,"median":-1.965361,"eighty":-1.010992,"marketCap":469033219},{"date":"2026-02-06","current":-2.579827,"twenty":-5.065967,"median":-1.978384,"eighty":-1.01346,"marketCap":415331486},{"date":"2026-02-13","current":-2.611764,"twenty":-5.054609,"median":-2.003915,"eighty":-1.013717,"marketCap":420473142},{"date":"2026-02-20","current":-2.87436,"twenty":-4.986457,"median":-2.025703,"eighty":-1.014247,"marketCap":462748974},{"date":"2026-02-27","current":-2.881457,"twenty":-4.928528,"median":-2.043785,"eighty":-1.01438,"marketCap":463891564},{"date":"2026-03-06","current":-2.977269,"twenty":-4.827435,"median":-2.086542,"eighty":-1.020777,"marketCap":479316530},{"date":"2026-03-13","current":-3.112116,"twenty":-4.780255,"median":-2.118493,"eighty":-1.024754,"marketCap":501025741},{"date":"2026-03-20","current":-3.030498,"twenty":-4.769593,"median":-2.129165,"eighty":-1.025937,"marketCap":487885955},{"date":"2026-03-27","current":-3.012142,"twenty":-4.692966,"median":-2.151832,"eighty":-1.027873,"marketCap":484930840},{"date":"2026-04-02","current":-3.286851,"twenty":-4.628408,"median":-2.225282,"eighty":-1.029368,"marketCap":530192007},{"date":"2026-04-10","current":-3.590425,"twenty":-4.584311,"median":-2.250455,"eighty":-1.030802,"marketCap":579160710},{"date":"2026-04-17","current":-3.571686,"twenty":-4.573206,"median":-2.388506,"eighty":-1.03519,"marketCap":576137951},{"date":"2026-04-24","current":-3.358479,"twenty":-4.567056,"median":-2.487395,"eighty":-1.037789,"marketCap":541746122},{"date":"2026-05-01","current":-3.302191,"twenty":-4.561844,"median":-2.543569,"eighty":-1.038061,"marketCap":532666578},{"date":"2026-05-08","current":-3.489816,"twenty":-4.559102,"median":-2.569768,"eighty":-1.044783,"marketCap":562931724},{"date":"2026-05-15","current":-4.15662,"twenty":-4.534296,"median":-2.581654,"eighty":-1.052413,"marketCap":650095346},{"date":"2026-05-22","current":-3.444499,"twenty":-4.49595,"median":-2.613087,"eighty":-1.058444,"marketCap":538719607},{"date":"2026-05-29","current":-3.347743,"twenty":-4.480996,"median":-2.625776,"eighty":-1.061012,"marketCap":523587034},{"date":"2026-06-05","current":-3.076828,"twenty":-4.471909,"median":-2.688295,"eighty":-1.061714,"marketCap":481215829},{"date":"2026-06-12","current":-3.045866,"twenty":-4.449191,"median":-2.698705,"eighty":-1.063858,"marketCap":476373405},{"date":"2026-06-18","current":-3.11166,"twenty":-4.431665,"median":-2.713919,"eighty":-1.066038,"marketCap":486663555},{"date":"2026-06-26","current":-3.187473,"twenty":-4.412024,"median":-2.725319,"eighty":-1.06856,"marketCap":498520738},{"date":"2026-07-02","current":-3.280765,"twenty":-4.395806,"median":-2.779231,"eighty":-1.069929,"marketCap":513111589},{"date":"2026-07-10","current":-3.813306,"twenty":-4.390126,"median":-2.789213,"eighty":-1.073668,"marketCap":596401029},{"date":"2026-07-17","current":-2.892048,"twenty":-4.36173,"median":-2.806937,"eighty":-1.084606,"marketCap":452316377},{"date":"2026-07-24","current":-2.833741,"twenty":-4.344692,"median":-2.815944,"eighty":-1.092409,"marketCap":443197095},{"date":"2026-07-31","current":-2.911484,"twenty":-4.315412,"median":-2.817583,"eighty":-1.094857,"marketCap":455356137},{"date":"2026-08-07","current":-3.01255,"twenty":-4.26922,"median":-2.824699,"eighty":-1.099263,"marketCap":471162893},{"date":"2026-08-14","current":-3.273726,"twenty":-4.239266,"median":-2.836847,"eighty":-1.106454,"marketCap":499695027},{"date":"2026-08-21","current":-3.293984,"twenty":-4.227182,"median":-2.842423,"eighty":-1.108015,"marketCap":502787199}],"updateTime":1787522804568},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"KYTX\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2629504374","title":"BUZZ-U.S. STOCKS ON THE MOVE-Adobe, GE Vernova, Calix","url":"https://stock-news.laohu8.com/highlight/detail?id=2629504374","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629504374?lang=en_us&edition=fundamental","pubTime":"2026-04-22 19:37","pubTimestamp":1776857863,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Adobe, GE Vernova, CalixWorkspace search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: https","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260422:nL6N4150TF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2326559502.SGD","LU2106854487.HKD","LU0069063385.USD","LU1923621640.USD","GEV","LU2125910179.SGD","LU1868836914.USD","TFX","LU0390134368.USD","LU1223082196.USD","BK4534","LU0075056555.USD","LU0300736062.USD","LU2210149790.SGD","IE0002270589.USD","LU2324357040.USD","LU1691799644.USD","LU0124384867.USD","IE00B894F039.SGD","LU0058720904.USD","BOEG","LU0557290698.USD","LU2125909247.SGD","LU0689472784.USD","LU0724618789.USD","LU1804176565.USD","LU0143863784.USD","LU2065171311.SGD","BK4583","LU0234570918.USD","IE00BKVL7J92.USD","LU1923623000.USD","BK4547","LU2298064838.USD","LU0965509101.SGD","LU1303367103.USD","LU2244417387.USD","BK4077","SG9999004303.SGD","LU0345780521.USD","BK4023","LU2063271972.USD","NWMX","LU0109391861.USD","LU0354030438.USD","IE00BQXX3D17.EUR","CDE","BK4121","BK4504","LU0345774391.USD","IE00BZ199S13.USD","HL","BK4527","LU0061474960.USD","LU2265009873.SGD","BK4020","LU1046421795.USD","LU1430597077.USD","LU1803068979.SGD","DGX","LU1868836591.USD","LU1883866441.USD","GEVX","LU1974910355.USD","BK4554","LU0823414478.USD","LU0648000940.SGD","SG9999001143.SGD","BK4196","LU0823417653.USD","LU1791710582.SGD","LU2506951958.HKD","LU2298322129.HKD","LU0345781412.USD","LU1551013342.USD","LU1023059063.AUD","LU0511384066.AUD","LU2023250504.SGD","LU0312595415.SGD","LU2462611646.USD","LU0342679015.USD","LU0097036916.USD","LU1093756168.USD","LU2065169927.USD","LU0289739343.SGD","SG9999001424.SGD","LU1854103824.USD","LU0630314457.HKD","LU0820561818.USD","LU1674673691.USD","LU2357125470.USD","LU0612318385.USD","IE0009356076.USD","LU2249611893.SGD","LU0868494617.USD","LU2125154935.USD","LU1978683503.SGD","LU0157215616.USD","LU2211814178.USD","NEMG","LU0950375773.USD","LU1868837300.USD","LU0345780281.USD","LU1868838027.USD","LU0823417737.USD","BK4210","LU1064131342.USD","IE00BD6J9T35.USD","LU1670628061.USD","LU0314104364.USD","LU1815333072.USD","LU0472753341.HKD","LU2264538146.SGD","LU0788108826.HKD","LU2236285917.USD","BK4564","LU0302445910.USD","LU1939255532.USD","LU1084165304.USD","LU1823568750.SGD","LU2098885051.SGD","HLXX","LU0868494708.USD","IE00B19Z9P08.USD","STX","ADBG","LU0107464264.USD","LU0143863198.USD","LU0528227936.USD","IE00B19Z3581.USD","IE00B19Z8W00.USD","LU0320765059.SGD","GB00BDT5M118.USD","BK4182","LU0266512127.USD","BK4581","LU0106261372.USD","LU0965509283.SGD","LU0456854461.SGD","LU1223082519.USD","LU2023251221.USD","LU0130103400.USD","LU2294711713.HKD","LU1983299246.USD","BK4566","LU1988902786.USD","AMRX","LU1429558221.USD","IE0004445239.USD","IE00B19Z3B42.SGD","LU2360107325.USD","LU0345774631.USD","SG9999001176.SGD","LU1623119135.USD","LU0354030511.USD","LU0689626769.HKD","LU1119994496.HKD","LU1721428933.USD","LU0203347892.USD","LU1670627923.USD","LU1280957306.USD","LU0109392836.USD","LU2506952170.USD","LU0942090050.USD","LU1435385759.SGD","LU1868837136.USD","NEM","IE00BQXX3C00.GBP","IE0034235188.USD","LU0187121727.USD","LU1548497426.USD","LU2506951875.HKD","BK4567","LU0289739699.SGD","LU2112291526.USD","LU1989764664.SGD","LU1861219969.SGD","BA","LU2125910336.SGD","ISRG","LU0477156797.USD","LU1712237335.SGD","IE000M9KFDE8.USD","TEL","LU0640476718.USD","LU0965509010.AUD","TH","LU1223083913.SGD","LU0820562030.AUD","LU0170899867.USD","IE00BZ9MQY76.HKD","BK4548","LU1057294990.SGD","DHR","LU0943347566.SGD","DJT","LU2023250843.SGD","LU0792757196.USD","LU1023059493.AUD","LU0368265764.SGD","LU0348723411.USD","BK4588","LU0266512473.USD","BK4139","LU2360032135.SGD","LU0672654240.SGD","LU0719512351.SGD","LU1861214812.USD","LU1061106388.HKD","LU0079474960.USD","LU0330918003.SGD","BK4170","BK4585","LU0347712357.USD","LU2237438978.USD","LU0203345920.USD","LU2355687059.USD","SGXZ57979304.SGD","LU2413666426.HKD","BK4543","BK4580","BK4522","SG9999001176.USD","LU0114720955.EUR","GEVG","BK4551","LU2238339852.HKD","LU0708995401.HKD","LU1868837565.USD","LU0496367417.USD","LU1235294995.USD","LU1093756325.SGD","BK4592","SGXZ51526630.SGD","LU0889565833.HKD","BK4145","LU0823416689.USD","SG9999000418.SGD","LU0957791311.USD","ISUL","LU0081259029.USD","IE00B19Z9505.USD","DJTU","TRUMP.USD.CC","IE00B19Z9Z06.USD","LU2498475776.HKD","LU1951198990.SGD","LU1261432733.SGD","BK4533","LU2210150020.SGD","LU0300736492.USD","LU0498741890.SGD","BK4017","LU2275660780.HKD","AU","LU1989764748.USD","HMY","SVM","LU1267930730.SGD","BK4528","LU0130518102.USD","LU2413666699.HKD","BK4007","SGXZ99366536.SGD","LU0823434740.USD","LU0096364046.USD","LU0788109121.HKD","LU0820561909.HKD","BK4516","LU0158827948.USD","LU0198837287.USD","LU1720051017.SGD","LU2458330243.SGD","LU0345780950.USD","BK4082","LU2506951792.HKD","LU2089283258.USD","KYTX","LU1551013425.SGD","BK4142","LU1201861165.SGD","LU1633808545.USD","LU2065170008.USD","LU0289961442.SGD","IE00BZ1G4Q59.USD","LU2506952097.USD","BK4570","LU1854104046.USD","BK4532","LU0654597011.USD","LU1366333091.USD","LU0055631609.USD","LU1674673428.USD","LU2357305700.SGD","IE0004091025.USD","SGXZ23171101.USD","ADBE","IE0004086264.USD","LU2095319765.USD","LU1868836757.USD","LU1791710400.SGD","BK4207","LU0498741114.HKD","LU0124676726.USD","LU2125909593.SGD","GFI","BOEU","IE00B5TLWC47.USD","IE00B19Z8X17.USD","LU1923622614.USD","IE00BYQQ9H92.USD","LU0823434583.USD","LU0861579265.USD","LU0061475181.USD","LU0057025933.USD","BK4512","LU0006306889.USD","LU0175139822.USD","LU1917777945.USD","LU1951200564.SGD","LU0823414551.USD","LU1778281490.HKD","LU0082616367.USD","LU0278409577.USD","LU0612318971.USD","LU1267930813.SGD","LU0432979614.USD","LU2317271919.USD","EXK","SGXZ81514606.USD","LU1983260115.SGD","LU2458330169.SGD","LU0724618433.USD","LU2433249047.HKD","LU1366192091.USD","LU0289960550.SGD","LU0122379950.USD","LU0889566641.SGD","IE00BQXX3F31.USD","LU0238689110.USD","BK4187","BOED","LU0234572021.USD","LU2125154778.USD","SG9999013999.USD","LU1720051108.HKD","IE00BFXG0V08.USD","LU0882574055.USD","LU2089284900.SGD","CALX","LU2065171402.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629043456","title":"Top Premarket Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2629043456","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629043456?lang=en_us&edition=fundamental","pubTime":"2026-04-22 19:34","pubTimestamp":1776857688,"startTime":"0","endTime":"0","summary":"Huachen AI Parking Management Technology  shares were up 52% in Wednesday premarket activity, adding to Tuesday's gain.Poet Technologies  stock was 20% higher, extending gains from the previous session.Kyverna Therapeutics  shares were up 14% after the company reported overnight that a single dose of miv-cel in its KYSA-8 study \"delivered rapid, statistically significant and clinically meaningful improvements\" throughout all primary and secondary endpoints at 16 weeks.Adobe  stock was 3.1% higher, a day after the company said its board approved a new share buyback authorization, giving the company authority to buy back up to $25 billion in shares through April 30, 2030.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["KYTX","BK4533","LU1366333091.USD","LU0965509010.AUD","LU1712237335.SGD","LU2360032135.SGD","LU0861579265.USD","BK4141","BK4585","LU0234572021.USD","LU0170899867.USD","LU2458330169.SGD","SGXZ99366536.SGD","LU0342679015.USD","LU2125154778.USD","LU0868494617.USD","LU0672654240.SGD","LU2023251221.USD","IE00BFXG0V08.USD","LU0289961442.SGD","BK4023","BK4528","LU2357305700.SGD","LU0082616367.USD","BK4527","LU1815333072.USD","SGXZ51526630.SGD","LU1119994496.HKD","BK4149","LU1623119135.USD","IE00B5TLWC47.USD","BK4554","SG9999000418.SGD","LU1548497426.USD","LU2210150020.SGD","IE0009356076.USD","LU0345774631.USD","BK4588","IE00BQXX3D17.EUR","BK4592","LU0289739343.SGD","LU0889565833.HKD","LU2125154935.USD","LU0314104364.USD","LU0158827948.USD","LU2095319765.USD","LU0157215616.USD","HCAI","BK4566","LU1267930730.SGD","LU0061474960.USD","LU0345774391.USD","LU0965509283.SGD","LU2458330243.SGD","LU0957791311.USD","LU0057025933.USD","LU0511384066.AUD","LU1720051017.SGD","LU0942090050.USD","LU0106261372.USD","LU2210149790.SGD","BK4581","LU0557290698.USD","LU0109392836.USD","LU1691799644.USD","LU0965509101.SGD","IE00BQXX3F31.USD","BK4534","LU0708995401.HKD","LU1084165304.USD","LU1720051108.HKD","LU0234570918.USD","LU0472753341.HKD","LU0198837287.USD","LU0109391861.USD","LU2317271919.USD","ADBE","LU1778281490.HKD","LU0081259029.USD","LU1674673691.USD","IE00BYQQ9H92.USD","LU0320765059.SGD","LU1803068979.SGD","LU2236285917.USD","LU0348723411.USD","LU0719512351.SGD","BK4567","LU0889566641.SGD","LU1046421795.USD","LU1674673428.USD","LU0792757196.USD","BK4139","LU1235294995.USD","LU1261432733.SGD","LU2237438978.USD","POET","LU0868494708.USD","IE00BQXX3C00.GBP","BK4543","LU0006306889.USD","LU2089284900.SGD","IE00B19Z9505.USD","SG9999001424.SGD","LU2089283258.USD","LU0069063385.USD","SGXZ81514606.USD","LU1823568750.SGD","ADBG","LU1633808545.USD","LU1267930813.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629017990","title":"Kyverna Shares Rise Premarket After Promising Trial of Neurological Product","url":"https://stock-news.laohu8.com/highlight/detail?id=2629017990","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629017990?lang=en_us&edition=fundamental","pubTime":"2026-04-22 18:35","pubTimestamp":1776854100,"startTime":"0","endTime":"0","summary":"Kyverna Therapeutics' stock was higher before the market's open after a treatment for a rare neurological condition showed promise in a mid-stage clinical trial.Shares of Kyverna were up 20% at $11.68 in premarket trading.The Emeryville, Calif., biotechnology company said its mivocabtagene autoleucel, or KYV-101, product was tested on patients with stiff person syndrome in a phase II trial. After 16 weeks on the treatment, the majority of the 26 patients with the autoimmune condition regained function and one-third of them were able to walk at a typical adult speed.\"We see compelling evidence that a one-time therapy can reset the immune system, reverse the course of disease, and free patients from lifelong treatment burden,\" said Chief Executive Warren Biddle, in a statement.Canadian singer Celine Dion suffers from stiff person syndrome and supports research into the neurological condition. The lead investigator for the trial, Dr. Amanda Piquet, is the Celine Dion Foundation endowed ch","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KYTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629017506","title":"BUZZ-Kyverna jumps as rare muscle disorder cell therapy shows strong mid-stage results","url":"https://stock-news.laohu8.com/highlight/detail?id=2629017506","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629017506?lang=en_us&edition=fundamental","pubTime":"2026-04-22 18:33","pubTimestamp":1776854017,"startTime":"0","endTime":"0","summary":"BUZZ-Kyverna jumps as rare muscle disorder cell therapy shows strong mid-stage results** Shares of biotech firm Kyverna Therapeutics KYTX.O jump 20.6% to $11.71 premarket** Co says its experimental cell therapy miv-cel showed strong results in a mid-stage study for stiff person syndrome, a rare neurological disorder that causes severe muscle stiffness and painful spasms** Co says a single dose led to rapid and lasting improvements in walking and mobility for most patients in the trial** Says 81% of patients saw meaningful gains in walking speed, while about two-thirds no longer needed walking aids after 16 weeks** Says all patients were able to stop immune-suppressing drugs, the current standard treatment that often provides limited relief** Says the therapy was generally well tolerated, with some manageable side effects such as temporary low white blood cell counts** As of last close, stock up ~3% YTD  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260422:nL4N4150Z6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629012198","title":"Kyverna Therapeutics Shares Jump 21% Premarket After Co's Therapy Improves Mobility in Mid-Stage Stiff Person Syndrome Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2629012198","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629012198?lang=en_us&edition=fundamental","pubTime":"2026-04-22 18:18","pubTimestamp":1776853093,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260422:nFWN41506Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KYTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629092056","title":"Kyverna Therapeutics (KYTX) Stock Surges 24% After Hours: Why Is It Moving?","url":"https://stock-news.laohu8.com/highlight/detail?id=2629092056","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629092056?lang=en_us&edition=fundamental","pubTime":"2026-04-22 14:44","pubTimestamp":1776840248,"startTime":"0","endTime":"0","summary":"Kyverna Therapeutics Inc. shares surged 24% after hours following positive registrational trial results for miv-cel in stiff person syndrome, showing significant improvement in walking speed.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/equities/26/04/51960000/kyverna-therapeutics-kytx-stock-surges-24-after-hours-why-is-it-moving","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4150","BK4561","OPEX","BK4079","KYTX","OPEG","BK4562","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629017066","title":"BRIEF-Kyverna Therapeutics Announces Positive Primary Analysis Results From KYSA-8 Trial Of Miv-Cel In SPS","url":"https://stock-news.laohu8.com/highlight/detail?id=2629017066","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629017066?lang=en_us&edition=fundamental","pubTime":"2026-04-22 06:51","pubTimestamp":1776811911,"startTime":"0","endTime":"0","summary":"BRIEF-Kyverna Therapeutics Announces Positive Primary Analysis Results From KYSA-8 Trial Of Miv-Cel In SPSApril 22 (Reuters) - Kyverna Therapeutics Inc KYTX.O:KYVERNA THERAPEUTICS INC - ANNOUNCES POSI","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260421:nFWN41414C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629066019","title":"Kyverna Therapeutics Inc - Trial Meets All Secondary Endpoints With Significant Improvements in SPS","url":"https://stock-news.laohu8.com/highlight/detail?id=2629066019","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629066019?lang=en_us&edition=fundamental","pubTime":"2026-04-22 06:50","pubTimestamp":1776811827,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260421:nFWN41414C:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KYTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629066012","title":"Kyverna Therapeutics Inc - Announces Positive Primary Analysis Results From Kysa-8 Trial of Miv-Cel in SPS","url":"https://stock-news.laohu8.com/highlight/detail?id=2629066012","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629066012?lang=en_us&edition=fundamental","pubTime":"2026-04-22 06:50","pubTimestamp":1776811827,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260421:nFWN41414C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KYTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629667210","title":"Kyverna says miv-cel meets primary endpoint in stiff person syndrome trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2629667210","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629667210?lang=en_us&edition=fundamental","pubTime":"2026-04-22 06:45","pubTimestamp":1776811516,"startTime":"0","endTime":"0","summary":"Kyverna disclosed positive primary analysis from KYSA-8, registrational Phase 2 trial of miv-cel in stiff person syndrome, with data presented in a late-breaking oral session at AAN Annual Meeting.Single-dose treatment produced rapid, durable clinical improvement in mobility and disability measures, with patients able to stop chronic immunotherapies.Safety profile supported outpatient use, with no severe cytokine release syndrome or serious neurotoxicity reported.Kyverna is preparing a BLA submission for stiff person syndrome, positioning miv-cel as a potential first approved therapy for the indication.Management scheduled an investor call for April 22, 2026 at 7:00 am ET to discuss KYSA-8 results, with updated Phase 2 generalized myasthenia gravis data from KYSA-6 also presented at AAN.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260421:nNDLmL0zT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","IE00BKPKM429.USD","BK4112","BK4585","KYTX","BK4139","SG9999014039.USD","SG9999014005.SGD","LU2095319765.USD","BK4588","IE00BN0W2V16.EUR","IE00B3QW5Z07.USD","NDAQ","LU2210150020.SGD","LU2210149790.SGD","LU0314104364.USD","IE00BN0W2W23.USD","IE00B64PRP62.GBP","IE00BN0W2T93.GBP","SG9999014013.SGD","SG9999014021.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629720709","title":"Kyverna Shares Rise on Positive Long-Term Trial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2629720709","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629720709?lang=en_us&edition=fundamental","pubTime":"2026-04-21 01:44","pubTimestamp":1776707040,"startTime":"0","endTime":"0","summary":"Kyverna Therapeutics shares rose after the company shared positive longer-term data from a Phase 2 trial of an autoimmune treatment.The stock gained 13% to $11.27 on Monday. Shares have climbed 19% this year.The late-stage clinical biopharmaceutical company said updated data from the trial of miv-cel in patients with myasthenia gravis, an autoimmune disorder, showed deep and durable responses across all key clinical outcome measures.There was also sustained benefit observed out to one year following a single dose of miv-cel, Kyverna said. The treatment was also well tolerated, the company added.All of the patients treated achieved clinically meaningful, rapid and sustained reductions in trial endpoint scores from the baseline, Kyverna said.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KYTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628725741","title":"Kyverna Therapeutics presents longer-term Phase 2 data for Miv-cel","url":"https://stock-news.laohu8.com/highlight/detail?id=2628725741","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628725741?lang=en_us&edition=fundamental","pubTime":"2026-04-20 21:12","pubTimestamp":1776690744,"startTime":"0","endTime":"0","summary":"Kyverna Therapeutics (KYTX) announced positive longer-term follow-up data from the Phase 2 portion of its registrational KYSA-6 trial of miv-cel in...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/kyverna-therapeutics-presents-longer-term-phase-2-data-for-miv-cel-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/kyverna-therapeutics-presents-longer-term-phase-2-data-for-miv-cel-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KYTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628740718","title":"Kyverna says miv-cel shows durable gMG responses through 52 weeks in Phase 2 KYSA-6 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2628740718","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628740718?lang=en_us&edition=fundamental","pubTime":"2026-04-20 20:03","pubTimestamp":1776686603,"startTime":"0","endTime":"0","summary":"Kyverna reported longer-term Phase 2 results for miv-cel in generalized myasthenia gravis during an oral presentation at American Academy of Neurology Annual Meeting.Follow-up showed rapid, durable symptom improvement across key clinical assessments, with responses sustained for up to one year in patients with available data.Patients were able to stop chronic immunosuppressive therapies through 24 weeks, supporting Kyverna’s strategy to position miv-cel as a single-dose, drug-free remission approach.Safety profile remained supportive of outpatient use, with no severe cytokine release syndrome or neurotoxicity events reported.Kyverna is enrolling Phase 3 portion of KYSA-6, with trial design also slated for presentation at AAN on April 21, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260420:nNDL2jh1Vn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KYTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628740179","title":"Kyverna Therapeutics Inc - 100% of Patients Achieved Rapid, Sustained Improvements in Mg-Adl and Qmg at 24 Weeks","url":"https://stock-news.laohu8.com/highlight/detail?id=2628740179","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628740179?lang=en_us&edition=fundamental","pubTime":"2026-04-20 20:02","pubTimestamp":1776686572,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260420:nFWN4130S2:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KYTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628740178","title":"Kyverna Therapeutics Inc - Announces Positive Longer-Term Phase 2 Data for Miv-Cel in Generalized Myasthenia Gravis","url":"https://stock-news.laohu8.com/highlight/detail?id=2628740178","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628740178?lang=en_us&edition=fundamental","pubTime":"2026-04-20 20:02","pubTimestamp":1776686572,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260420:nFWN4130S2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KYTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627463171","title":"Kyverna Therapeutics announces annual shareholder meeting via webcast","url":"https://stock-news.laohu8.com/highlight/detail?id=2627463171","media":"Reuters","labels":["conferences","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627463171?lang=en_us&edition=fundamental","pubTime":"2026-04-14 04:03","pubTimestamp":1776110602,"startTime":"0","endTime":"0","summary":"Kyverna Therapeutics schedules annual shareholder meeting in virtual format on May 27, 2026.Shareholders will vote to elect two Class II directors to serve terms running to 2029.Meeting agenda includes ratification of BDO USA as independent auditor for fiscal 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kyverna Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 13, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260413:nNDL33YmyJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KYTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626184398","title":"Kyverna to present pivotal KYSA-8 miv-cel data in stiff person syndrome at AAN","url":"https://stock-news.laohu8.com/highlight/detail?id=2626184398","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626184398?lang=en_us&edition=fundamental","pubTime":"2026-04-09 20:04","pubTimestamp":1775736284,"startTime":"0","endTime":"0","summary":"Kyverna scheduled April 22, 2026 conference call to discuss primary analysis from KYSA-8 registrational trial of miv-cel in stiff person syndrome.Data will be presented in future as oral presentations at American Academy of Neurology annual meeting in Chicago, April 18-22, 2026.Kyverna also plans to share longer-term follow-up from KYSA-6 Phase 2 study of KYV-101 in generalized myasthenia gravis.Update frames miv-cel as key late-stage asset in neuroimmunology, with near-term readouts that could shape regulatory strategy in stiff person syndrome.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kyverna Therapeutics Inc. published the original content used to generate this news brief on April 09, 2026, and is solely responsible for the inf","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260409:nNDL983DGg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626871411","title":"Kyverna Therapeutics to Host Conference Call on New Data Across Neuroimmunology Franchise at AAN 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2626871411","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626871411?lang=en_us&edition=fundamental","pubTime":"2026-04-09 20:00","pubTimestamp":1775736000,"startTime":"0","endTime":"0","summary":"EMERYVILLE, Calif., April  09, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Kyverna, Nasdaq: KYTX), a late-stage clinical biopharmaceutical company focused on developing cell therapies for pat","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/09/3270858/0/en/Kyverna-Therapeutics-to-Host-Conference-Call-on-New-Data-Across-Neuroimmunology-Franchise-at-AAN-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AAN","IE0031619046.USD","BK4588","IE00B19Z4B17.USD","BK4139","BK4585","SOC","BK4181","BK4230","BK4178","BK4022","BK4213","CAR","IE00B66KJ199.SGD","IE00B7SZL793.SGD","MG","KYTX","BK4218","BK4123","HST"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624680339","title":"BRIEF-Kyverna Therapeutics Enters Open Market Sale Agreement With Jefferies Dated March 27, 2025 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2624680339","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624680339?lang=en_us&edition=fundamental","pubTime":"2026-04-03 05:26","pubTimestamp":1775165211,"startTime":"0","endTime":"0","summary":"BRIEF-Kyverna Therapeutics Enters Open Market Sale Agreement With Jefferies Dated March 27, 2025 - SEC FilingApril 2  - Kyverna Therapeutics Inc KYTX.O:KYVERNA THERAPEUTICS INC - ENTERS OPEN MARKET SALE AGREEMENT WITH JEFFERIES LLC DATED MARCH 27, 2025 - SEC FILINGKYVERNA THERAPEUTICS INC - MAY OFFER UP TO $100 MILLION OF COMMON STOCK - SEC FILINGSource text: [ID:n0001193125-26-140377]Further company coverage: KYTX.O ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nFWN40L0YL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623312861","title":"J.P. Morgan Sticks to Their Buy Rating for Kyverna Therapeutics, Inc. (KYTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2623312861","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623312861?lang=en_us&edition=fundamental","pubTime":"2026-03-30 19:35","pubTimestamp":1774870535,"startTime":"0","endTime":"0","summary":"In a report released today, from J.P. Morgan maintained a Buy rating on Kyverna Therapeutics, Inc., with a price target of $30.00. In addition to J...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/j-p-morgan-sticks-to-their-buy-rating-for-kyverna-therapeutics-inc-kytx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/j-p-morgan-sticks-to-their-buy-rating-for-kyverna-therapeutics-inc-kytx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KYTX"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":4,"totalSize":96,"code":"91000000","status":"200"}]}}